Check Cap Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals

Company anticipates initiation of the first part of its u.s. pivotal study in april 2022 isfiya, israel , april 7, 2022 /prnewswire/ -- check-cap ltd. (the "company" or "check-cap") (nasdaq: chek), (nasdaq: chekz), a clinical stage medical diagnostics company advancing the development of c-scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (crc), today announced financial results for the fourth quarter and full year ended december 31, 2021.

Isfiya, israel, feb. 7, 2022 /prnewswire/ -- check-cap ltd. (the "company" or "check-cap") (nasdaq: chek), (nasdaq: chekz), a clinical stage medical diagnostics company advancing the development of c-scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer (crc), today announced that the company has received approval from the u.s. food and drug administration (fda) for its amended investigational device exemption (ide) application, enabling initiation of the u.s. pivotal study.

Isfiya, israel, jan. 5, 2022 /prnewswire/ -- check-cap ltd. (the "company" or "check-cap") (nasdaq: chek), (nasdaq: chekz), a clinical stage medical diagnostics company advancing the development of c-scan ® , the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer (crc), today issued the following letter from its chief executive officer, alex ovadia, to its shareholders and the investment community: dear check-cap shareholders, we have greatly appreciated your support throughout 2021, a year during which we have continued our progress as we prepare to initiate our u.s. pivotal study of c-scan, including strengthening our manufacturing capacity, clinical affairs team and our balance sheet.

Isfiya, israel, dec. 23, 2021 /prnewswire/ -- check-cap ltd. (the "company" or "check-cap") (nasdaq: chek), (nasdaq: chekz), a clinical stage medical diagnostics company advancing the development of c-scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (crc), today announced that the company received a letter from the nasdaq listing qualifications (the "letter"), indicating that the company is not in compliance with the minimum bid price requirement for continued listing set forth in listing rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

Isfiya, israel, june 30, 2021 /prnewswire/ -- check-cap ltd. (the "company" or "check-cap") (nasdaq: chek), (nasdaq: chekz), a clinical stage medical diagnostics company advancing the development of c-scan®, the first and only patient-friendly, preparation-free screening test, to detect polyps before they may transform into colorectal cancer (crc), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 25,925,926 of the company's ordinary shares and accompanying short-term warrants to purchase up to an aggregate of 25,925,926 of the company's ordinary shares in a registered direct offering.

Here we discuss ShockWave Medical (SWAV), CheckCap (CHEK) and Biosig Technologies (BSGM) that have the potential to outperform their industry going forward.

The FDA has approved Check-Cap Ltd's (NASDAQ: CHEK) amended Investigational Device Exemption (IDE) application to initiate the U.S. pivotal study of C-Scan. The U.S. pivotal study consists of two parts.

Some of the best penny stocks 2021 has offered were some of… The post 5 Penny Stocks To Buy According To Analysts & Price Targets Up To 175% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

A penny stocks list for the end of October The post Top Penny Stocks To Buy For Under $5 On WeBull appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech penny stocks are in focus; here's 4 to watch right now The post Best Biotech Penny Stocks to Buy in July 2021? 6 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The stock price of Check Cap Ltd (NASDAQ: CHEK) fell by over 10% during intraday trading. This is why it happened.

ISFIYA, Israel, June 30, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test, to detect polyps before they may transform into colorectal cancer (CRC), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 25,925,926 of the Company's ordinary shares and accompanying short-term warrants to purchase up to an aggregate of 25,925,926 of the Company's ordinary shares in a registered direct offering.

Why should you check out CHEK stock? An FDA approval, along with an impressive year-end capital position, provide a solid case for Check-Cap.

ISFIYA, Israel, March 19, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free, screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results for the fourth quarter and full year ended December 31, 2020.

The stock price of Check Cap Ltd (NASDAQ: CHEK) fell by over 10% pre-market. This is why it happened.